Literature DB >> 25404200

The German guidelines for the treatment of anxiety disorders.

Borwin Bandelow1, Thomas Lichte, Sebastian Rudolf, Jörg Wiltink, Manfred E Beutel.   

Abstract

A consensus group consisting of 36 experts representing 20 leading German specialist societies and patient self-help organizations developed evidence-based recommendations for the treatment of anxiety disorders in Germany. These were based on a systematic review of randomized controlled trials on anxiety disorders (n = 403) and on preexisting German and international guidelines. According to the consensus committee, anxiety disorders should be treated with psychotherapy or pharmacological drugs or a combination of both. Cognitive behavioral therapy (CBT) was regarded as the psychological treatment with the highest level of evidence. Psychodynamic therapy (PDT) was recommended for cases in which CBT was not effective or not available or in which PDT was the informed patient's preferred option. First-line drugs for anxiety disorders include selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors. After remission, medications should be continued for 6-12 months. When either drug or psychotherapy was not effective, treatment should be switched to the other approach or to a combination of both. For patients non-responsive to standard treatments, alternative strategies are suggested. When developing a treatment plan, efficacy, side effects, costs and the preference of the patient should be considered. A large amount of data available from randomized controlled trials permit the formulation of robust evidence-based recommendations for the treatment of anxiety disorders. The recommendations were not only developed for the special situation in Germany, but may also be helpful for developing treatment plans in other countries.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404200     DOI: 10.1007/s00406-014-0563-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  22 in total

Review 1.  Antidepressants in pregnancy: a systematic review.

Authors:  Adaobi Udechuku; Tram Nguyen; Rebecca Hill; Klara Szego
Journal:  Aust N Z J Psychiatry       Date:  2010-11       Impact factor: 5.744

2.  [Mental disorders in the general population : Study on the health of adults in Germany and the additional module mental health (DEGS1-MH)].

Authors:  F Jacobi; M Höfler; J Strehle; S Mack; A Gerschler; L Scholl; M A Busch; U Maske; U Hapke; W Gaebel; W Maier; M Wagner; J Zielasek; H-U Wittchen
Journal:  Nervenarzt       Date:  2014-01       Impact factor: 1.214

3.  Prevalence and treatment of mental disorders, 1990 to 2003.

Authors:  Ronald C Kessler; Olga Demler; Richard G Frank; Mark Olfson; Harold Alan Pincus; Ellen E Walters; Philip Wang; Kenneth B Wells; Alan M Zaslavsky
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

4.  Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT.

Authors:  Andrew T Gloster; Hans-Ulrich Wittchen; Franziska Einsle; Thomas Lang; Sylvia Helbig-Lang; Thomas Fydrich; Lydia Fehm; Alfons O Hamm; Jan Richter; Georg W Alpers; George W Alpers; Alexander L Gerlach; Andreas Ströhle; Tilo Kircher; Jürgen Deckert; Peter Zwanzger; Michael Höfler; Volker Arolt
Journal:  J Consult Clin Psychol       Date:  2011-06

Review 5.  How to develop cost-conscious guidelines.

Authors:  M Eccles; J Mason
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

6.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.

Authors:  Borwin Bandelow; Leo Sher; Robertas Bunevicius; Eric Hollander; Siegfried Kasper; Joseph Zohar; Hans-Jürgen Möller
Journal:  Int J Psychiatry Clin Pract       Date:  2012-04-30       Impact factor: 1.812

7.  Generalized anxiety and depression in primary care: prevalence, recognition, and management.

Authors:  Hans-Ulrich Wittchen; Ron C Kessler; Katja Beesdo; Petra Krause; Michael Höfler; Jürgen Hoyer
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

Review 8.  The size and burden of mental disorders and other disorders of the brain in Europe 2010.

Authors:  H U Wittchen; F Jacobi; J Rehm; A Gustavsson; M Svensson; B Jönsson; J Olesen; C Allgulander; J Alonso; C Faravelli; L Fratiglioni; P Jennum; R Lieb; A Maercker; J van Os; M Preisig; L Salvador-Carulla; R Simon; H-C Steinhausen
Journal:  Eur Neuropsychopharmacol       Date:  2011-09       Impact factor: 4.600

Review 9.  Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review.

Authors:  Marco Tuccori; Arianna Testi; Luca Antonioli; Matteo Fornai; Sabrina Montagnani; Narcisa Ghisu; Rocchina Colucci; Tiberio Corona; Corrado Blandizzi; Mario Del Tacca
Journal:  Clin Ther       Date:  2009-06       Impact factor: 3.393

10.  Pregabalin for the treatment of generalized anxiety disorder: an update.

Authors:  David S Baldwin; Khalil Ajel; Vasilios G Masdrakis; Magda Nowak; Rizwan Rafiq
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

View more
  17 in total

1.  DGPPN guideline on anxiety disorders and cognitive dysfunction in the elderly or patients with multiple sclerosis.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08       Impact factor: 5.270

2.  [Treatment preferences of elderly patients with mental disorders].

Authors:  F H Boehlen; W Herzog; I Maatouk; K-U Saum; H Brenner; B Wild
Journal:  Z Gerontol Geriatr       Date:  2015-06-02       Impact factor: 1.281

3. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

Review 4.  Internet psychotherapeutic interventions for anxiety disorders - a critical evaluation.

Authors:  Borwin Bandelow; Dirk Wedekind
Journal:  BMC Psychiatry       Date:  2022-06-29       Impact factor: 4.144

5.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

6.  Diagnosis and Treatment Procedures for Patients With Anxiety Disorders by the Psychiatric Consultation Liaison Service in a General Hospital in Germany: A Retrospective Analysis.

Authors:  Christina Anderson; Deborah Tauch; Arnim Quante
Journal:  Prim Care Companion CNS Disord       Date:  2015-10-08

7.  Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013.

Authors:  Simon J C Davies; Binu Jacob; David Rudoler; Juveria Zaheer; Claire de Oliveira; Paul Kurdyak
Journal:  Ther Adv Psychopharmacol       Date:  2017-12-05

8.  Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.

Authors:  Antonio W Zuardi; Natália P Rodrigues; Angélica L Silva; Sandra A Bernardo; Jaime E C Hallak; Francisco S Guimarães; José A S Crippa
Journal:  Front Pharmacol       Date:  2017-05-11       Impact factor: 5.810

9.  Differential effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment.

Authors:  Lisa-Marie Brunner; Franziska Maurer; Kevin Weber; Johannes Weigl; Vladimir M Milenkovic; Rainer Rupprecht; Caroline Nothdurfter; Andreas Mühlberger
Journal:  Psychopharmacology (Berl)       Date:  2022-03-12       Impact factor: 4.415

Review 10.  Treatment of anxiety disorders.

Authors:  Borwin Bandelow; Sophie Michaelis; Dirk Wedekind
Journal:  Dialogues Clin Neurosci       Date:  2017-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.